oa Foreword [ Current Vascular Pharmacology is 10 Years Old! ]

Current Vascular Pharmacology (CVP) has come a long way 10 years after its launching. We obtained listing on MEDLINE several years ago and our impact factor is now 3.184 [Institute of Scientific Information (ISI) website]. This places us on the top 16% of all journals listed on the ISI website. Most medical journals do not even achieve listing on that website. This year, we already have a very interesting choice of articles that cover a wide field of vascular pharmacology. In this issue, the “Hot Topic” is endothelial function. We have other hot topic issues coming during the year as well as general articles. These include, themes like statin-induced myopathy, smoking, diabetes, hypertension, metabolic syndrome and thrombosis. One innovation during 2011 was that we now consider original research papers as well as reviews and editorials. However, these original research papers will be restricted to 20% of the journal content. Thus, CVP remains primarily a review journal. We prefer original research papers to be focused on human studies; however, we can make exceptions. We always try to be as flexible as possible (within reason!). Therefore, we also do not impose strict restrictions with regard to how many words or references are allowed. Another novel feature for CVP was that we publish guidelines (e.g. European Society of Vascular Surgery - carotid disease prevention) and Expert Panel statements (e.g. regarding “small, dense low density lipoproteins” and “post-prandial lipaemia”)….